Solid Biosciences (SLDB): Vestal Point Capital discloses 4.8% ownership, including warrant shares

Rhea-AI Filing Summary

Vestal Point Capital, LP and its Chief Investment Officer, Ryan Wilder, report beneficial ownership of Solid Biosciences Inc. common stock through a fund and a managed account they advise. Their position totals 4,833,796 shares of common stock, including shares issuable upon exercise of pre-funded common stock purchase warrants.

The reported holdings represent 4.8% of Solid Biosciences’ common stock, based on 98,449,606 shares outstanding as of May 8, 2026, and assuming exercise of the warrants. Voting and dispositive power over all reported shares is shared, with no sole voting or dispositive power reported. The filers state that the filing should not be construed as an admission of beneficial ownership for all purposes.

Key Figures

Shares beneficially owned: 4,833,796 shares Ownership percentage: 4.8% Shares via pre-funded warrants: 2,673,796 shares +3 more

6 metrics

Shares beneficially owned 4,833,796 shares Total Solid Biosciences common shares reported by Vestal Point Capital and Ryan Wilder

Ownership percentage 4.8% Portion of Solid Biosciences common stock class represented by reported holdings

Shares via pre-funded warrants 2,673,796 shares Common shares issuable upon exercise of pre-funded common stock purchase warrants

Shares outstanding baseline 98,449,606 shares Solid Biosciences common stock outstanding as of May 8, 2026 used for ownership calculation

Shared voting power 4,833,796 shares Number of shares over which the reporting persons have shared voting power

Shared dispositive power 4,833,796 shares Number of shares over which the reporting persons have shared dispositive power

Key Terms

beneficial owner, pre-funded Common Stock purchase warrants, shared voting power, shared dispositive power, +1 more

5 terms

beneficial owner regulatory

"for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

pre-funded Common Stock purchase warrants financial

"includes 2,673,796 shares of Common Stock issuable upon exercise of pre-funded Common Stock purchase warrants"

A pre-funded common stock purchase warrant is a contract that gives an investor the right to receive a company’s common shares later after having paid nearly the full share price up front, leaving only a very small remaining payment to convert the warrant into an actual share. Think of it like reserving a product by paying almost everything now and paying a tiny balance later; it provides immediate capital to the company, limits immediate dilution of outstanding shares, and lets investors manage ownership limits and timing of when they actually hold tradable stock.

shared voting power financial

"Shared Voting Power 4,833,796.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 4,833,796.00"

Schedule 13G regulatory

"for the purposes of Section 13 of the Securities Exchange Act of 1934"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

What stake in Solid Biosciences Inc. (SLDB) does Vestal Point Capital report?

Vestal Point Capital and Ryan Wilder report beneficial ownership of 4,833,796 shares of Solid Biosciences common stock, representing 4.8% of the outstanding class, including shares issuable upon exercise of pre-funded common stock purchase warrants.

How many Solid Biosciences (SLDB) shares are tied to pre-funded warrants?

The reported position includes 2,673,796 shares of Solid Biosciences common stock issuable upon exercise of pre-funded common stock purchase warrants held by the Vestal Point fund and managed account advised by Vestal Point Capital.

What is the basis for the 4.8% ownership percentage in SLDB?

The 4.8% ownership is calculated using 98,449,606 shares of Solid Biosciences common stock outstanding as of May 8, 2026, as reported in a Form 10-Q, and assumes exercise of the pre-funded warrants held.

Does Vestal Point Capital have sole or shared voting power over its SLDB shares?

Vestal Point Capital and Ryan Wilder report 0 shares with sole voting power and 4,833,796 shares with shared voting power, matching the number of shares over which they also report shared dispositive power.

Who are the reporting persons in the Solid Biosciences (SLDB) Schedule 13G/A?

The reporting persons are Vestal Point Capital, LP, a Delaware limited partnership and investment adviser, and Ryan Wilder, its Chief Investment Officer and Managing Partner, with respect to shares held by a fund and a managed account they advise.

Where are Vestal Point Capital and Ryan Wilder based according to the SLDB filing?

The business address for both Vestal Point Capital and Ryan Wilder is listed as 632 Broadway, Suite 602, New York, NY 10012. Solid Biosciences’ principal executive offices are at 500 Rutherford Avenue, Third Floor, Charlestown, Massachusetts 02129.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:18 PM Accepted by SEC EDGAR 08/14/2026 - 04:08 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Solid Biosciences Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

83422E204

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 83422E204

1

Names of Reporting Persons

Vestal Point Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,833,796.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,833,796.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,833,796.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.8 %

12

Type of Reporting Person (See Instructions)

IA, PN

Comment for Type of Reporting Person: Includes 2,673,796 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of pre-funded Common Stock purchase warrants (the "Warrants").

SCHEDULE 13G

CUSIP Number(s): 83422E204

1

Names of Reporting Persons

Ryan Wilder

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,833,796.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,833,796.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,833,796.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.8 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Includes 2,673,796 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of the Warrants.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Solid Biosciences Inc.
(b)	Address of issuer's principal executive offices: 500 Rutherford Avenue, Third Floor, Charlestown, Massachusetts 02129
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of common stock, par value $0.001 per share (the "Common Stock"), of Solid Biosciences Inc. (the "Company"), and shares of Common Stock issuable upon exercise of the Warrants directly held by the Vestal Point Fund and Account; and (ii) Mr. Ryan Wilder ("Mr. Wilder"), the Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock and shares of Common Stock issuable upon exercise of the Warrants directly held by the Vestal Point Fund and Account. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012.
(c)	Citizenship: The Investment Manager is a Delaware limited partnership. Mr. Wilder is a citizen of the United States.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 83422E204
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 98,449,606 shares of Common Stock outstanding as of May 8, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 12, 2026, and assumes the exercise of the Warrants held by the Vestal Point Fund and Account.
(b)	Percent of class: 4.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vestal Point Capital, LP

Signature:	/s/ Ryan Wilder
Name/Title:	By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
Date:	08/14/2026

Ryan Wilder

Signature:	/s/ Ryan Wilder
Name/Title:	Ryan Wilder, Individually
Date:	08/14/2026